TD Cowen analyst Ryan Langston raised the firm’s price target on UnitedHealth (UNH) to $335 from $275 and keeps a Hold rating on the shares. The firm said they see a potentially favorable 2027 MA Advance Notice as a positive leading indicator for the company. They see potential upside to MA margin recovery expectations for 2027 and beyond, but continue to be cautious into 2026 primarily from the continued impacts from v28.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- Cautious Hold on UnitedHealth Amid Medicare Advantage Uncertainties and Raised Price Target
- Goldman Sachs Says Buying the UnitedHealth (UNH) Stock Dip Isn’t a Bad Idea
- UnitedHealth Stock (UNH) Scores Goldman Sachs’ Buy Rating, Truist Lifts Price Target
- AMD upgraded, Micron downgraded: Wall Street’s top analyst calls
- UnitedHealth price target raised to $410 from $365 at Truist